Bionano Genomics Inc. (NASDAQ:BNGO) had 7.47 million shares traded in the previous session. The stock ended the trading day at $6.16, representing a -3.30 percent (-$0.21) intraday loss. The BNGO share has a 52-week high of $15.69, which is down -154.71 from that high but still represents a stunning 92.37 percent gain since the share price plunged to a 52-week low of $0.47. The company has a market valuation of $1.74 billion, with an average intraday trading volume of 11.02 million shares over the last ten days and 22.28 million shares for the last three months.
Analysts unanimously recommended that Bionano Genomics Inc. (BNGO) be purchased. This equates to a 1.20 average rating. BNGO has received a Sell rating from 0 analyst(s) out of 4 who have looked at the stock. 0 analyst(s) advocate holding the stock, 0 recommend overweighting it, and 4 recommend buying it. The stock has been rated Underweight by 0 analyst(s). The current quarter’s earnings per share (EPS) are predicted to be -$0.04.
Information on Bionano Genomics Inc. (NASDAQ:BNGO).
Bionano Genomics Inc. (BNGO) fell -3.30 percent in the previous session after trading in the green for the previous five sessions. In intraday trading on Thursday, July 22nd, the stock fell -3.30 percent to $6.16, a weekly high. The stock has moved -13.60 percent in 30 days and has a 5-day price performance of 5.48 percent. The overall pricing performance for the year is 590.97 percent based on these engagements. Bionano Genomics Inc. (NASDAQ:BNGO) has a short interest of 38.52 million shares, implying that shorts have 1.65 day(s) to cover.
Wall Street analysts’ consensus price objective is $11.50, implying a 46.43 percent rise over the stock’s current price. The forecast’s extremes result in target low and high prices of $10.00 and $14.00, respectively. As a result, BNGO is currently trading at a -127.27 percent discount to the target high and a -62.34 percent discount to the target low.
Estimates and projections from Bionano Genomics Inc. (BNGO).
Bionano Genomics Inc. has surpassed its competition in terms of share price when compared to the industry in which it works, according to statistics. Bionano Genomics Inc. (BNGO) has lost -25.51 percent in the last six months, with a year-to-date growth rate of 51.28 percent versus 8.80 percent for the industry. Analysts, on the other hand, are raising their growth forecasts for fiscal year 2021. Revenue is expected to increase by 55.60 percent this quarter and then by 37.50 percent the following quarter. Revenue is expected to climb by 88.80% over the previous financial year, according to the rating firms’ predictions.
According to four analysts, revenue for the current quarter will be $3.52 million (s). Meanwhile, 4 analyst(s) predict sales growth of $4.2 million by the end of September 2021. Sales for the corresponding quarters reached $1.18 million and $2.2 million, respectively, according to the earnings report from the previous fiscal year’s results. In this situation, analysts estimate revenues to increase by 197.80 percent in the current quarter and then by 91.30 percent in the next quarter.
In 2021, earnings are expected to return 80.20 percent.
Dividends from BNGO’s
Between June 21 and June 25, Bionano Genomics Inc. will release its next quarterly earnings report. It’s crucial to remember, however, that the dividend yield ratio is only a guideline.
Bionano Genomics Inc. (NASDAQ:BNGO)’s Major holders
Major shareholders of Bionano Genomics Inc. (NASDAQ:BNGO) Bionano Genomics Inc. insiders own 0.34 percent of total outstanding shares, while institutional investors own 15.86 percent, with a float of 15.91 percent. The company’s largest stakeholder is Renaissance Technologies, LLC, with 144 institutions owning stock. The corporation held over 9.49 million shares (or 3.40 percent of all shares) valued at $76.65 million as of March 30, 2021.
Vanguard Group, Inc. (The) is the second largest institutional position, accounting for approximately 3.33 percent of outstanding shares with 9.3 million shares. These shares were worth $75.11 million at the market price on March 30, 2021.
Vanguard Total Stock Market Index Fund and Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF are also the Mutual Funds with the greatest holdings of Bionano Genomics Inc. (BNGO) shares. Vanguard Total Stock Market Index Fund owns around 6.19 million shares, according to data from March 30, 2021. With a market value of $49.99 million, this represents little over 2.22 percent of the company’s total shares. The other fund manager has somewhat less, at 3.15 million shares, or about 1.13 percent of the stock, which is worth roughly $19.46 million, according to the same data.